Global Health Estimates: www.who.int/news-room/fact-sheets
Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels. https://ehnheart.org/images/CVD-statistics-report-August-2017.pdf
Townsend N, Kazakiewicz D, Wright F, Timmis A, Huculeci R, Torbica A, et al. Epidemiology of CV disease in Europe. Nat Rev Cardiol. 2022;19:133–43. https://doi.org/10.1038/s41569-021-00607-3
Zamorano J, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and CV toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and CV toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. https://doi.org/10.1093/eurheartj/ehw211
US Cancer Statistics. https://gis.cdc.gov/Cancer/USCS/#/Demographics
Ibrahim A, Chamseddine N, El-Cheikh J, Hanna C, Moukadem W, Nasr F, et al. Management of multiple myeloma in the middle east: unmet needs, challenges and perspective. Clin Hematol Int. 2022. https://doi.org/10.1007/s44228-022-00017-3
Oliveira M, Naaktgeboren W, Hua A, Ghosh A, Oakervee H, Hallam S, et al. Optimising cardiovascular care of patients with multiple myeloma. Heart. 2021;107:1774–82. https://doi.org/10.1136/heartjnl-2020-318748
Kistler K, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin Lymphoma Leuk. 2017;17:89–96. https://doi.org/10.1016/j.clml.2016.11.009
Morris T, Drake M, Kettle P, McGuigan T, Leahy M, O’Dwyer M, et al. How to simplify the evaluation of newly introduced chemotherapeutic interventions in myeloma. Clin Hematol Int. 2021;3:27–33. https://doi.org/10.2991/chi.k.210201.001
Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, et al. Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. Int J Hematol. 2009;90:635–42. https://doi.org/10.1007/s12185-009-0445-8
Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J, et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol. 2000;63:125–30. https://doi.org/10.1002/(sici)1096-8652(200003)63:3<125::aid-ajh3>3.0.co;2-s
Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:356–9. https://doi.org/10.1002/clc.20904
Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46:1575–9. https://doi.org/10.1080/10428190500235884
Yanamandra U, Gupta S, Khadwal A, Malhotra P. Melphalan-induced cardiotoxicity: ventricular arrhythmias. BMJ Case Rep. 2016;2016:bcr2016218652. https://doi.org/10.1136/bcr-2016-218652
Kozelj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Radio Oncol. 2013;47:161–5. https://doi.org/10.2478/raon-2013-0019
Kumar L, Sahoo RK, Kumar S, Baa AK, Tansir G, Pathak N. for AIIMS Myeloma Group et al. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. Leuk Lymphoma. 2023;64:378–87. https://doi.org/10.1080/10428194.2022.2148214
Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol. 2017;3:980–8. https://doi.org/10.1001/jamaoncol.2016.3350
Delforge M, Bladé J, Dimopoulos M, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11:1086. https://doi.org/10.1016/S1470-2045(10)70068-1
Das A, Dasgupta S, Gong Y, Shah U, Fradley M, Cheng R, et al. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Haematol Oncol. 2022;40:233–42. https://doi.org/10.1002/hon.2959
Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–52. https://doi.org/10.1038/leu.2009.147
Al-Yafeai Z, Ghoweba M, Ananthaneni A, Abduljabar H, Aziz D. Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study. Br J Clin Pharm. 2023;89:641–8. https://doi.org/10.1111/bcp.15499
Jacob R, Strati P, Palaskas N, Lopez-Mattei J, Marmagkiolis K, Buja L, et al. Lenalidomide-induced myocarditis, rare but possibly fatal toxicity of a commonly used immunotherapy. J Am Coll Cardiol Case Rep. 2020;2:2095–2100. https://doi.org/10.1016/j.jaccas.2020.07.033
Verbesselt M, Meekers E, Vandenberghe P, Delforge M, Vandenbriele C. Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. Eur Heart J Case Rep. 2022;6:1–7. https://doi.org/10.1093/ehjcr/ytac093
Mateos M, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6:e459. https://doi.org/10.1016/s2352-3026(19)30110-3
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, et al. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017;178:547–60. https://doi.org/10.1111/bjh.14708
Reneau JC, Asante D, van Houten H, Sangaralingham LR, Buadi FK, Lerman A, et al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. Am J Hematol. 2017;92:E15–E17. https://doi.org/10.1002/ajh.24599
Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res. 2008;79:472–80. https://doi.org/10.1093/cvr/cvn083
Versari D, Herrmann J, Gössl M, Mannheim D, Sattler K, Meyer FB, et al. Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2132–9. https://doi.org/10.1161/01.ATV.0000232501.08576.73
Rahman M, Ball S, Paz P, Elmassry M, Vutthikraivit W, Bandyopadhya D, et al. Heart failure with carfilzomib in patients with multiple myeloma: a meta-analysis of randomized controlled trials. J Card Fail. 2021;27:610–2. https://doi.org/10.1016/j.cardfail.2020.07.006
Chari A, Stewart A, Russell S, Moreau P, Herrmann J, Banchs J, et al. Analysis of carfilzomib CV safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2:1633–44. https://doi.org/10.1182/bloodadvances.2017015545
Buck B, Kellett E, Addison D, Vallakati A. Carfilzomib-induced cardiotoxicity: an analysis of the FDA adverse event reporting system (FAERS). J Saudi Heart Assoc. 2022;34:134–41. https://doi.org/10.37616/2212-5043.1311
Waxman A, Clasen S, Hwang W, Garfall A, Vogl D, Carver J, et al. Carfilzomib-associated CV adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519. https://doi.org/10.1001/jamaoncol.2017.4519
Moreau P, Mateos M, Berenson J, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953–64. https://doi.org/10.1016/s1470-2045(18)30354-1
Wu P, Oren O, Gert M, Yang E. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22:66. https://doi.org/10.1007/s11912-020-00931-w
Forghani P, Rashid A, Sun F, Liu R, Li D, Lee M, et al. Carfilzomib treatment causes molecular and functional alterations of human induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2021;10:e022247. https://doi.org/10.1161/jaha.121.022247
Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, et al. Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: result of a multi-omics integrative analysis. Front Cardiovasc Med. 2021;8:645122. https://doi.org/10.3389/fcvm.2021.645122
Cornell R, Ky B, Weiss B, Dahm C, Gupta D, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946–55. https://doi.org/10.1200/jco.19.00231
Dimopoulos M, Quach H, Mateos M, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186–97. https://doi.org/10.1016/S0140-6736(20)30734-0
Terpos E, Stamatelopoulos K, Makris N, Georgiopoulos G, Ntanasis-Stathopoulos I, Terpos M, et al. Daratumumab may attenuate cardiac dysfunction related to carfilzomib in patients with relapsed/refractory multiple myeloma: a prospective study. Cancers (Basel). 2021;13:5057. https://doi.org/10.3390/cancers13205057
Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021;137:1154–65. https://doi.org/10.1182/blood.2020008209
Moreau P, Dimopoulos M, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361–71. https://doi.org/10.1016/s0140-6736(21)00592-4
Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178:896–905. https://doi.org/10.1111/bjh.14787
Simbaqueba CC, Aponte MP, Kim P, Deswal A, Palaskas NL, Iliescu C, et al. Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias. J Immunother Precis Oncol. 2020;3:113–20. https://doi.org/10.36401/JIPO-20-10
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://doi.org/10.1016/S0140-6736(21)00933-8
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265–74. https://doi.org/10.1200/JCO.22.00842
Lesokhin A, Arnulf B, Niesvizky R, Mohty M, Bahlis N, Tomasson M, et al. Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). J Clin Oncol. 2022;40:8006–8006
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232–44. https://doi.org/10.1056/NEJMoa2204591
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–74. https://doi.org/10.1182/blood-2014-12-615187
Yao Y, Sui WW, Liao AJ, Wang W, Chen LJ, Chu XX, et al. Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age Ageing. 2022;51:afab211. https://doi.org/10.1093/ageing/afab211
Gamarra Samaniego MDP, Blanquicett CJ, Araujo Castillo RV, Chavez JC, Beltrán Garate BE. Selected domains within a comprehensive geriatric assessment in older patients with non-hodgkin lymphoma are highly associated with frailty. Clin Hematol Int. 2022;4:35–43. https://doi.org/10.1007/s44228-022-00005-7
Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953–63. https://doi.org/10.1182/blood-2018-09-874396
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A. ASPIRE Investigators et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52. https://doi.org/10.1056/NEJMoa1411321
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R. ENDEAVOR Investigators et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. https://doi.org/10.1016/S1470-2045(15)00464-7
Danhof S, Schreder M, Rasche L, Strifler S, Einsele H, Knop S. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97:25–32. https://doi.org/10.1111/ejh.12677
Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, et al. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med. 2021;10:70–78. https://doi.org/10.1002/cam4.3568
Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39:2430–42. https://doi.org/10.1200/JCO.21.00972